Nearly Half of Giant Cell Arteritis Patients on Actemra for a Year Stay in Remission After Stopping It
"Giant cell arteritis requires ongoing management, but it does not necessarily require continuous treatment.” In 2017, tocilizumab (Actemra), a biologic drug that inhibits interleukin-6 (IL-6), was FDA-approved for giant cell…